Atopy, psoriasis and autoimmune disease: the stem-cell claims examined

On its 淸(Rejuvenation)CELL programme page, Cheongdam Cell Clinic lists atopy, psoriasis and autoimmune diseases together in one sentence under 'difficult to cure diseases', without explaining the mechanism specific to each. This article separates each condition for clarity, since the clinic's statement covers conditions with very different natures.

Atopic dermatitis is a chronic inflammatory skin condition common in both children and adults, involving a compromised skin barrier combined with allergic reactions. Standard treatment includes regular moisturising, topical steroids or other agents depending on severity, and trigger avoidance; severe cases may use biologics such as dupilumab.

Psoriasis is a skin condition caused by the immune system triggering abnormally rapid skin-cell turnover, producing thick red plaques with silvery-white scale. Treatment ranges from topical agents and UV phototherapy to oral medication or biologics in severe cases — an approach with clear clinical evidence from international dermatology societies.

'Autoimmune diseases' is a broad term covering many conditions such as lupus, autoimmune thyroid disease, or rheumatoid arthritis, each with very different target organs and severity. Grouping this term broadly on the clinic's website without naming a specific disease makes it hard to assess in practice how the programme relates to any one condition.

The shared thread linking these three conditions is immune-system dysregulation. Certain stem cells, especially mesenchymal stem cells, have been studied across several autoimmune diseases on the hypothesis that they may help rebalance immune-cell activity. However, most research remains early-to-mid-stage, with results varying by disease type and the patient group studied.

Patients with atopy, psoriasis or autoimmune disease who are on topical steroids, immunosuppressants or biologics should disclose their full treatment history to Cheongdam Cell Clinic's doctors before deciding, and should not stop medication prescribed by their dermatologist or immunologist on their own.

In summary, mentioning these three conditions together on the clinic's website is a broad communication linked to the immune-rebalancing concept, not confirmation that the programme has specific efficacy for any one disease. Patients should keep standard treatment from specialists as their foundation and view the stem-cell programme as a supplementary option requiring careful consideration.